RAC1 and cancer: Currently, two compounds, NSC23766 and EHT1864, have been extensively utilized as RAC1 inhibitors in preclinical studies, exhibiting high specificity in inhibiting RAC1 activity and demonstrating therapeutic benefits in RAS-mutant cancers, including pancreatic cancer (PDAC) and non-small-cell lung cancer (NSCLC) [43,44].